SkylineDx’s Merlin Test Recognized by NCCN for Melanoma

By Karen Roman SkylineDx said its Merlin CP-GEP molecular test is uniquely recognized by the National Comprehensive Cancer Network (NCCN) for predictive use in select T1 and T2 melanoma patients. The ...

Merlin CP-GEP Becomes the First and Only Gene Expression Profile (GEP) Test Recommended by NCCN® Cutaneous Melanoma Guidelines to Assess Metastatic Risk

SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice Guidelines in Oncology for Cutaneous Melanoma (Version 1.2026), recognizing Merlin ...
Healio

Speaker discusses predictive power of Merlin test for low-, high-risk melanoma

Please provide your email address to receive an email when new articles are posted on . The Merlin test, a clinical-pathologic and gene expression profile, was able to successfully classify 37% of ...